- Home
- About
- Section Advisors
- Meet Our Field Medical Affairs Team
- Speakers Bureau
- Supporting Organizations
- Contact Us
- PsychU For You
- Topics
- Mental Health Disorders
- Agitation
- Bipolar Disorder
- Depression
- PTSD/Trauma
- Schizophrenia
- Substance Use Disorders
- Topics of Interest
- Care Coordination
- Digital Health
- Diversity, Equity, & Inclusion
- Health Care Policy, Quality & Payer Administration
- Long-Term Care
- Stigma
- Suicide Awareness
- Wellness
- Events
- Content
- Infographics
- Learning Tracks
- Podcasts
- Shareable/Downloadable Content
- Videos
- PsychUSim
- PsychU Roleplay
- Frameworks In Health & Quality Resources
- Mental Health System Guidebooks
- Psychiatric Scales
- Psychopharmacology
- Supporting Organizations
Factors in Designing & Evaluating Clinical Trials for App-Based Interventions
Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
Factors in Designing & Evaluating Clinical Trials for App-Based Interventions
As digital mental health interventions are becoming an integral part of our healthcare landscape, there is a need to better understand digital clinical trials and how to evaluate their outcomes to support clinical decision making. In this webinar, Dr. Sara Morimoto, PsyD will share her expertise in developing and testing app-based mental health interventions. In this context, she will discuss design aspects and other factors that may require special consideration when evaluating clinical outcomes for app-based treatments.
Objectives:
- Review the requirements for FDA Clearance of Prescription Digital Therapeutics (PDT)
- Review considerations in the evaluation of clinical trials for digital therapeutics (DTx)
- Discuss the importance of clinically meaningful data in the development and assessment of DTx and impact on patient care.
Featuring
Sarah S. Morimoto, PsyD
Associate Professor – Spencer Fox Eccles School of Medicine at the University of Utah, Salt Lake City, UT
MoreSarah Shizuko Morimoto, PsyD, is Associate Professor, Population Health Sciences, Division of Health Systems Innovation and Research, as well as Director of the Neurotherapeutics Lab and Director of Cognitive Remediation in Psychiatry at the University of Utah School of Medicine in Salt Lake City. Dr Morimoto’s research encompasses the full range of digital cognitive remediation intervention development, from identifying targeted and clinically relevant cognitive deficits to developing computerized paradigms and conducting clinical trials. Dr Morimoto received her PsyD in clinical psychology from the PGSP-Stanford PsyD Consortium through Palo Alto University and Stanford University School of Medicine, Department of Psychiatry and Behavioral Sciences, California. She completed a clinical internship at Beth Israel Deaconess/Massachusetts Mental Health Center/Harvard Medical School Department of Psychiatry, Boston, Massachusetts, a fellowship in clinical neuropsychiatry at New York-Presbyterian/Weill Cornell Medical Center, and a fellowship in geriatric mood disorders at Weill Cornell Institute of Geriatric Psychiatry at Weill Cornell Medical College.Scott Schepers, PhD (OPDC)
Medical Science Liaison
Sara Morimoto is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc.
Scott Schepers is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc.
Disclaimer: PsychU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), Otsuka America Pharmaceutical, Inc. (OAPI), and Lundbeck, LLC – committed supporters of the mental health treatment community. The opinions expressed by PsychU’s contributors are their own and are not endorsed or recommended by PsychU or its sponsors. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing PsychU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC, OAPI, and / or Lundbeck, LLC.
August 2024 US.CORP.X.24.00250Related Events
-
The Danger of Post-Traumatic Stress Disorder (PTSD) Stigma Among Marginalized Communities
October 10 12:00 pm to 1:00 pm -
Addressing Caregiver Burden & Identifying Agitation in Alzheimer’s Dementia
November 13 12:00 pm to 1:00 pm
Registration
Log in to register
Related Resources
-
The Agitation in Alzheimer’s Screener for Caregivers (AASC™) Scale Brochure
Downloadable Resource October 3, 2024The Agitation in Alzheimer’s Screener for Caregivers (AASC™) is a brief screening tool based on the International Psychogeriatric Association (IPA) consensus definition for agitation in cognitive disorders and was designed…
-
ICD-10-CM Diagnosis Code Quick Reference Guide
Infographic October 2, 2024This list includes ICD-10 codes that may be relevant for patients with agitation associated with dementia due to Alzheimer’s disease.
-
Talking Points (Part II): Primary Care on MDD – David Lewis
Podcast October 1, 2024Listen to Amica Simmons-Yon, PharmD, PhD as she spills the tea on a new Talking Points Series from Primary Care on Major Depressive Disorder (MDD) with special guest, David E….
Join today for instant access to all PsychU content, events, and more!
Membership is free!
"*" indicates required fields
Join PsychU Today to receive a wide array of tools and benefits
- Join our multidisciplinary community that is improving mental health care… together
- Quickly learn more about the topics you're interested in
- Access an award-winning library of on-demand mental health resources
- Gain key insights from industry expert & thought leaders
Stay Connected: